Philip Morris International CFO Emmanuel Babeau Says Co Does Not Expect Any Significant Volume From IQOS U.S. Launch In 2024; Nicotine Pouch Brand Zyn Will Gradually Return To Normal Stock Levels Throughout 2025
Portfolio Pulse from Benzinga Newsdesk
Philip Morris International's CFO, Emmanuel Babeau, announced that the company does not anticipate significant volume from the IQOS U.S. launch in 2024. Additionally, the nicotine pouch brand Zyn is expected to gradually return to normal stock levels throughout 2025.
October 22, 2024 | 1:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Philip Morris International does not expect significant sales volume from the IQOS launch in the U.S. in 2024, which may temper investor expectations for short-term revenue growth. Zyn's stock levels are expected to normalize by 2025, indicating a gradual recovery in supply.
The announcement suggests that the IQOS launch in the U.S. will not significantly impact Philip Morris's sales in 2024, which could lead to neutral short-term stock performance. However, the normalization of Zyn's stock levels by 2025 indicates a positive long-term outlook.
CONFIDENCE 95
IMPORTANCE 70
RELEVANCE 90